Klas Wiman

Klas Wiman

Professor, Senior
Visiting address: BioClinicum, J6:10, Akademiska stråket 1, 17164 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Schlisio Wiman, 171 77 Stockholm
Part of:

About me

  • I am Professor of Molecular Cell and Tumor Biology at Karolinska Institutet since 1999. My main research interest is cancer and novel cancer therapy. For more than three decades, I have studied the tumor suppressor gene TP53. I was coordinator of an EU Integrated project (Mutp53) with 23 partners and a budget of 8 M Euros 2004-2009, and have co-edited two books on p53 (Springer 2005 and 2012). I have also co-founded the company Aprea Therapeutics with colleagues with the aim of developing novel p53-targeted anti-cancer drugs. More recently, my research has been supported by an ERC Advanced Grant.

Research

  • My laboratory performs research on p53 and the p53 tumor suppressor pathway, the p53 target gene Zmat3 (Wig-1), and therapeutic reactivation of mutant p53. We have identified the molecule APR-246 that can trigger apoptosis in TP53 mutant tumor cells and inhibit tumor growth in vivo in mice. It targets the cellular redox balance as well. APR-246 has been tested in several clinical trials in patients with MDS/AML. We are exploring the use of APR-246 for cancer prevention. We are also working on novel strategies for pharmacological induction of translational readthrough for reactivation of nonsense mutant TP53 in tumors.

Selected publications

Articles

All other publications

Employments

  • Professor, Senior, Department of Oncology-Pathology, Karolinska Institutet, 2025-2025
  • Professor, Department of Oncology-Pathology, Karolinska Institutet, 1999-2025

Degrees and Education

  • Docent, Karolinska Institutet, 1987

News from KI

Events from KI